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EDITORS’ COMMENTTrans-Atlantic Debate: Whether Level I Evidence Comparing Thoracic
Endovascular Repair and Medical Management is Necessary for
Uncomplicated Type B Aortic DissectionsThoracic endovascular repair (TEVAR) has not yet demon-
strated superiority over medical treatment for patients with
uncomplicated type B aortic dissection (BAD).1 In this clinical
setting, rupture is uncommon except in cases with a large
aneurysm at the entry site or large false lumen dilatation.
However, aortic branch occlusion by the propagation of the
false lumen and subsequent malperfusion syndrome may
complicate the initial presentation. Until now a complication-
speciﬁc approach has been adopted as the standard of care,
but endovascular treatment (TEVAR) sealing the aortic tear
and achieving depressurization of the false lumen has the
potential to reduce both early and late complications, and to
change treatment strategies. However, as explained by our
debaters, many questions remain, and it is not clear if we
need more evidence before accepting TEVAR as routine in
patients with uncomplicated BAD.
UNCOMPLICATED ACUTE BAD
Meta-analysis2 of three studies comparing medical therapy
and TEVAR for acute uncomplicated BAD3e5 found a lower
early mortality rate with medical therapy compared with
TEVAR (odds-ratio [OR]: 0.50; 95% conﬁdence interval [CI]:
0.27e0.95). In three other studies comparing TEVAR and
open surgery,5e7 the pooled early mortality rate was
signiﬁcantly higher for open surgery (OR: 2.66; 95% CI:
1.37e5.17). However, in these non-randomized studies,
comparison of medical therapy versus TEVAR or versus open
surgery for acute uncomplicated BAD is often biased with an
overestimation of low complication rates in patients at
lower risk and usually assigned to medical therapy. Never-
theless, according to these data, there is evidence, although
not from level 1 studies, that patients with uncomplicated
acute BAD do well with medical treatment alone.2 This
strategy was debated by Jan Brunkwall, who supports the
use of TEVAR in acute BAD following data from the Acute
Dissection Stent-graft Or Best medical treatment (ADSORB)
study,8 which showed that TEVAR allows true lumen
expansion. However, in this trial low recruitment resulted in
an underpowered study not being able to demonstrate a
potential difference in mortality between the two groups.
UNCOMPLICATED CHRONIC BAD
Regarding chronic BAD, the Investigation of STEnt Grafts in
Aortic Dissection (INSTEAD) randomized controlled trial
(RCT)9 showed that medical therapy with close surveillance
was associated with excellent all-cause and aorta-related1078-5884/$ e see front matter
http://dx.doi.org/10.1016/j.ejvs.2013.06.016survival rates that were not improved by TEVAR. In detail,
the survival rate at 2 years was 88.9%  3.7% with TEVAR
versus 95.6%  2.5% with medical treatment (p ¼ .18).
Similarly, the aorta-related 2-year survival was comparable
among the two groups. As discussed by our debaters, with 11
deaths, the 2-year death rate did not meet the assumption of
28 events for statistical power. Finally, the cluster end-point of
aorta-related death, crossover/conversion, and ancillary
procedures was not statistically different between the two
groups with freedom from event in 72.5%  5.5% of the pa-
tients withmedical treatment versus 77.2% 5.0% for TEVAR
(p ¼ .65). It should be emphasized that in this RCT, most pa-
tients were randomized 2weeks after the onset of symptoms,
thus those with early complications, who would most likely
beneﬁt from TEVAR, were not included in the study cohort. In
addition, among the seven patients who died in the TEVAR
group, four of them with malperfusion or impending rupture
should have been excluded from this RCT aimed at elective
management of uncomplicated chronic BAD.10 Despite these
criticisms, INSTEADdthe only RCT for chronic BADdsupports
a complication-speciﬁc approach instead of the routine use of
TEVAR. However, some encouraging data were also reported
in this trial, which showed aortic remodeling at 2 years with
true lumen recovery and false lumen thrombosis in 91.3% of
patients receiving TEVAR versus 19.4% of patients in the
medical group. This was not the endpoint of the study, but
aortic remodeling may be considered as a surrogate for pre-
vention of late aneurysm formation.11
After an extensive review of the literature, our debaters
proposed different strategies, and we suggest that medical
management with close imaging follow-up is probably the
best strategy for uncomplicated BAD. However, as demon-
strated by this debate, the evidence favoring this strategy is
limited. Considering the lack of power of the ADSORB and
INSTEAD trials, we need large studies stratiﬁed by type and
timing with long-term follow-up to provide optimal treat-
ment guidelines.
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